ES3060528T3 - Kx2-391/kx-01 for use in the treatment of actinic keratosis - Google Patents

Kx2-391/kx-01 for use in the treatment of actinic keratosis

Info

Publication number
ES3060528T3
ES3060528T3 ES18764980T ES18764980T ES3060528T3 ES 3060528 T3 ES3060528 T3 ES 3060528T3 ES 18764980 T ES18764980 T ES 18764980T ES 18764980 T ES18764980 T ES 18764980T ES 3060528 T3 ES3060528 T3 ES 3060528T3
Authority
ES
Spain
Prior art keywords
approximately
days
administered
subject
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18764980T
Other languages
English (en)
Spanish (es)
Inventor
Min-Fun Rudolf Kwan
Johnson Yiu-Nam Lau
E Douglas Kramer
David Lawrence Cutler
Jane Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atnx Spv LLC
Original Assignee
Atnx Spv LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3060528(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv LLC filed Critical Atnx Spv LLC
Application granted granted Critical
Publication of ES3060528T3 publication Critical patent/ES3060528T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18764980T 2017-03-10 2018-03-12 Kx2-391/kx-01 for use in the treatment of actinic keratosis Active ES3060528T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Publications (1)

Publication Number Publication Date
ES3060528T3 true ES3060528T3 (en) 2026-03-26

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18764980T Active ES3060528T3 (en) 2017-03-10 2018-03-12 Kx2-391/kx-01 for use in the treatment of actinic keratosis

Country Status (23)

Country Link
US (3) US10617693B2 (https=)
EP (2) EP3592355B1 (https=)
JP (3) JP7502863B2 (https=)
KR (2) KR20240090837A (https=)
CN (1) CN110891575A (https=)
AU (2) AU2018231144B2 (https=)
BR (1) BR112019018687A2 (https=)
CA (1) CA3055938A1 (https=)
DK (1) DK3592355T3 (https=)
ES (1) ES3060528T3 (https=)
FI (1) FI3592355T3 (https=)
HR (1) HRP20260155T1 (https=)
IL (1) IL269182B2 (https=)
LT (1) LT3592355T (https=)
MX (2) MX387658B (https=)
NZ (1) NZ757105A (https=)
PL (1) PL3592355T3 (https=)
PT (1) PT3592355T (https=)
RS (1) RS67713B1 (https=)
SI (1) SI3592355T1 (https=)
TW (1) TWI841523B (https=)
WO (1) WO2018165647A1 (https=)
ZA (1) ZA202100106B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN117599189A (zh) * 2018-03-07 2024-02-27 慧源Spv公司 用于治疗过度增殖性皮肤障碍的组合物和方法
JP7296945B2 (ja) * 2018-03-28 2023-06-23 テルモ株式会社 医療デバイス
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
JP2024506240A (ja) * 2021-01-21 2024-02-13 サーナオミクス インコーポレイテッド 皮膚がんの治療のための組成物および方法
WO2025077886A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技(广州)有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ, エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
WO2008030892A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
WO2008144045A1 (en) 2007-05-17 2008-11-27 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
SI2378876T1 (sl) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Also Published As

Publication number Publication date
CN110891575A (zh) 2020-03-17
KR20190141661A (ko) 2019-12-24
DK3592355T3 (da) 2026-02-16
IL269182B2 (en) 2023-11-01
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
KR20240090837A (ko) 2024-06-21
AU2018231144B2 (en) 2023-12-21
JP2023015269A (ja) 2023-01-31
AU2024201828A1 (en) 2024-05-02
LT3592355T (lt) 2026-02-25
JP2025029010A (ja) 2025-03-05
US20180256589A1 (en) 2018-09-13
JP2020510042A (ja) 2020-04-02
HRP20260155T1 (hr) 2026-03-27
PT3592355T (pt) 2026-02-03
RU2019131757A3 (https=) 2021-05-31
TWI841523B (zh) 2024-05-11
EP4659740A3 (en) 2026-02-18
EP3592355A1 (en) 2020-01-15
US11497750B2 (en) 2022-11-15
TW201842913A (zh) 2018-12-16
US10617693B2 (en) 2020-04-14
EP3592355B1 (en) 2025-12-10
NZ757105A (en) 2026-02-27
RS67713B1 (sr) 2026-02-27
AU2024201828B2 (en) 2026-02-19
US20230172942A1 (en) 2023-06-08
SI3592355T1 (sl) 2026-04-30
BR112019018687A2 (pt) 2020-04-07
EP4659740A2 (en) 2025-12-10
WO2018165647A1 (en) 2018-09-13
MX2019010707A (es) 2020-01-15
FI3592355T3 (fi) 2026-02-13
AU2018231144A1 (en) 2019-10-03
ZA202100106B (en) 2022-08-31
IL269182A (en) 2019-11-28
EP3592355A4 (en) 2021-01-06
RU2019131757A (ru) 2021-04-12
MX387658B (es) 2025-03-18
JP7502863B2 (ja) 2024-06-19
IL269182B1 (en) 2023-07-01
PL3592355T3 (pl) 2026-04-07
CA3055938A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
ES3060528T3 (en) Kx2-391/kx-01 for use in the treatment of actinic keratosis
Dhar et al. Intralesional bleomycin in the treatment of cutaneous warts: a randomized clinical trial comparing it with cryotherapy
Pasricha et al. Treatment of skin diseases
JP7096332B2 (ja) 腫瘍処置誘導性の経口胃腸粘膜炎の予防および/または処置における使用のための組成物
US9901555B2 (en) Treatment of viral infections
US20160089362A1 (en) Method for Topically Treating Actinic Keratosis on the Trunk (except chest) or Extremities with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
RU2805929C2 (ru) Способы лечения и/или предотвращения актинического кератоза
HK40020549B (en) Kx2‑391/kx‑01 for use in the treatment of actinic keratosis
HK40020549A (en) Kx2‑391/kx‑01 for use in the treatment of actinic keratosis
US11642328B2 (en) Creatine, its derivatives, compositions and methods of use thereof
BR122025000862A2 (pt) Usos do composto kx-01 no tratamento e/ou prevenção da ceratose actínica
US20250099409A1 (en) Topical therapeutic
HK1190071A (en) The treatment of viral infections
HK1190071B (en) The treatment of viral infections